Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Concordia University Professor awarded grant to study molecular mechanisms of virulence factor protein

Concordia University is pleased to announce that Dr. Peter D. Pawelek, Assistant Professor, Department of Chemistry and Biochemistry was awarded a grant from the Thalassemia Foundation of Canada to study molecular mechanisms of a virulence factor protein from an opportunistic pathogen that affects thalassemia patients.

3 Mar 2010

Universal Detection Technology responds to HSPH survey on anthrax threat

Universal Detection Technology (www.udetection.com), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, responded today to a survey that says nearly a third of Americans would delay in taking an antibiotic recommended by public health officials in the wake of an anthrax detect.

3 Mar 2010

Agilent Technologies, NCFST enter into collaboration to develop new scientific methods for food testing

Agilent Technologies Inc. and the National Center for Food Safety and Technology today announced that they have entered into a collaboration to develop new scientific methods for food testing, with the goal of solving a wide range of persistent problems facing global food supply chains.

2 Mar 2010

Chitosan put forward as effective alternative to growth-promoting antibiotics in the diet of ruminants

The natural-occurring biopolymer known as chitosan is being put forward as an effective alternative to growth-promoting antibiotics in the diet of ruminants, according to research carried out by scientists at the Basque technological centre, Neiker-Tecnalia.

1 Mar 2010

New data shows Valortim antibody enhances human T cell response to B. anthracis

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new data from the Company's Valortim® anthrax anti-toxin program were presented at the 8th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Baltimore, Maryland, February 21-24, 2010.

25 Feb 2010

ViroPharma reports 76% growth in fourth-quarter net product sales

ViroPharma Incorporated reported today its financial results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

Prednisolone associated with recurrence of CAP after its withdrawal

Patients hospitalized with mild to moderate community-acquired pneumonia (CAP) should not be routinely prescribed prednisolone, a corticosteroid, as it is associated with a recurrence of symptoms after its withdrawal, according to the first randomized double-blind clinical trial to address the subject.

24 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.

23 Feb 2010

Solta Medical announces definitive agreement to acquire Aesthera

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.

23 Feb 2010

Catheter insertion technology patent acquired by Acacia Research subsidiary

Acacia Research Corporation announced today that a subsidiary has acquired patents for catheter insertion technology.

23 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

Hospital-acquired infections increase mortality rate and healthcare costs

Two common conditions caused by hospital-acquired infections (HAIs) killed 48,000 people and ramped up health care costs by $8.1 billion in 2006 alone, according to a study released today in the Archives of Internal Medicine.

23 Feb 2010

PositiveID, RECEPTORS announce successful completion of rapid virus detection system Phase I development

PositiveID Corporation, in conjunction with its development partner RECEPTORS LLC, announced today that it has successfully completed Phase I development of its rapid virus detection system, a non-invasive, point-of-care test to test patient samples and identify various forms of influenza within minutes. Phase II of the development, which the Company expects to complete by the end of 2010, is planned to launch in February 2010.

23 Feb 2010

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help develop the therapy.

22 Feb 2010

National poll examines public health response to anthrax attack

In a national poll aimed at helping with planning efforts for a public health response to a possible bioterrorism attack, researchers at the Harvard School of Public Health (HSPH) have found that, in response to a fictional scenario describing a significant anthrax attack in their city or town, most Americans (89%) will likely follow public health recommendations to obtain prophylactic antibiotics.

20 Feb 2010

Janssen-Cilag International's European MAA for ZEFTERA: CHMP adopts negative opinion

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on its Marketing Authorisation Application (MAA) for the antibiotic ZEFTERA(TM) (ceftobiprole medocaril), for the treatment of complicated skin and soft tissue infections.

19 Feb 2010

Polyphor discovers new class of antibiotics effective against multi-drug resistant Gram-negative bacteria

Today, Polyphor Ltd published the discovery of a new class of antibiotics with a novel mode of action (Science, VOL 327, ISSUE 5968). This proprietary new class of antibiotics is effective against multi-drug resistant Gram-negative bacteria, opening up new treatment options for serious and often life-threatening infections. The most advanced drug candidate in this new class, POL7080, selectively kills the dangerous bacteria Pseudomonas aeruginosa.

19 Feb 2010

Rib-X Pharmaceuticals co-founder discovers new ribosomal structures of antibiotics

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, and Yale University today announced the discovery by Thomas Steitz, Ph.D., co-founder of Rib-X and Yale University professor, of important new ribosomal structures of antibiotics, enabling the potential creation of novel treatments for drug resistant infections, including resistant tuberculosis (TB).

19 Feb 2010

Delay in Vibativ's approval for nosocomial pneumonia to reduce previously forecasted commercial impact

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that delays in the U.S. approval and launch of Theravance/Astellas's Vibativ (telavancin) for the treatment of nosocomial pneumonia will reduce by more than half the commercial impact that it was previously forecasted to garner in the methicillin-resistant Staphylococcus aureus (MRSA) drug market.

19 Feb 2010

Antibiotic News and Research

Further Reading

Concordia University Professor awarded grant to study molecular mechanisms of virulence factor protein

Universal Detection Technology responds to HSPH survey on anthrax threat

Agilent Technologies, NCFST enter into collaboration to develop new scientific methods for food testing

Chitosan put forward as effective alternative to growth-promoting antibiotics in the diet of ruminants

New data shows Valortim antibody enhances human T cell response to B. anthracis

ViroPharma reports 76% growth in fourth-quarter net product sales

Prednisolone associated with recurrence of CAP after its withdrawal

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

Solta Medical announces definitive agreement to acquire Aesthera

Catheter insertion technology patent acquired by Acacia Research subsidiary

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Hospital-acquired infections increase mortality rate and healthcare costs

PositiveID, RECEPTORS announce successful completion of rapid virus detection system Phase I development

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

National poll examines public health response to anthrax attack

Janssen-Cilag International's European MAA for ZEFTERA: CHMP adopts negative opinion

Polyphor discovers new class of antibiotics effective against multi-drug resistant Gram-negative bacteria

Rib-X Pharmaceuticals co-founder discovers new ribosomal structures of antibiotics

Delay in Vibativ's approval for nosocomial pneumonia to reduce previously forecasted commercial impact

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News